[go: up one dir, main page]

WO2008156701A3 - Hydroxamate inhibitors of insulin-degrading enzyme and uses thereof - Google Patents

Hydroxamate inhibitors of insulin-degrading enzyme and uses thereof Download PDF

Info

Publication number
WO2008156701A3
WO2008156701A3 PCT/US2008/007447 US2008007447W WO2008156701A3 WO 2008156701 A3 WO2008156701 A3 WO 2008156701A3 US 2008007447 W US2008007447 W US 2008007447W WO 2008156701 A3 WO2008156701 A3 WO 2008156701A3
Authority
WO
WIPO (PCT)
Prior art keywords
insulin
degrading enzyme
hydroxamate inhibitors
hydroxamate
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/007447
Other languages
French (fr)
Other versions
WO2008156701A2 (en
Inventor
Malcolm A Leissring
Dennis Selkoe
Gregory D Cuny
Sungwoon Choi
Ross L Stein
Benjamin Turk
Lewis C Cantley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Brigham and Womens Hospital Inc
Harvard University
Original Assignee
Yale University
Brigham and Womens Hospital Inc
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University, Brigham and Womens Hospital Inc, Harvard University filed Critical Yale University
Publication of WO2008156701A2 publication Critical patent/WO2008156701A2/en
Publication of WO2008156701A3 publication Critical patent/WO2008156701A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a novel therapeutic approach for the prevention and treatment of infections and for the treatment of diabetes wherein the degradation of insulin is reduced through inhibition of insulin-degrading enzyme (IDE) by hydroxamate inhibitors.
PCT/US2008/007447 2007-06-13 2008-06-13 Hydroxamate inhibitors of insulin-degrading enzyme and uses thereof Ceased WO2008156701A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93458707P 2007-06-13 2007-06-13
US60/934,587 2007-06-13

Publications (2)

Publication Number Publication Date
WO2008156701A2 WO2008156701A2 (en) 2008-12-24
WO2008156701A3 true WO2008156701A3 (en) 2009-02-26

Family

ID=40156847

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/007447 Ceased WO2008156701A2 (en) 2007-06-13 2008-06-13 Hydroxamate inhibitors of insulin-degrading enzyme and uses thereof

Country Status (1)

Country Link
WO (1) WO2008156701A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102369015A (en) * 2009-02-02 2012-03-07 雷蒙特亚特特拉维夫大学有限公司 Peptides, pharmaceutical compositions comprising same and uses thereof
EP2371421A1 (en) 2010-03-04 2011-10-05 Université de Lille 2 Droit et Santé Ligands of insulin degrading enzyme and their uses
WO2012016186A1 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Macrocyclic kinase inhibitors and uses thereof
WO2012017439A2 (en) 2010-08-04 2012-02-09 Ramot At Tel-Aviv University Ltd. Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases
FR2968560A1 (en) 2010-12-13 2012-06-15 Oreal USE OF THE IDE AS A BIOMARKER OF A CONDITION OF THE SCALP
JP6023192B2 (en) * 2011-07-01 2016-11-09 プレジデント アンド フェローズ オブ ハーバード カレッジ Macrocyclic insulin-degrading enzyme (IDE) inhibitors and uses thereof
WO2016172631A2 (en) 2015-04-24 2016-10-27 President And Fellows Of Harvard College Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof
EP3672939A1 (en) 2017-08-21 2020-07-01 Celgene Corporation Processes for preparation of (s)-tert-butyl 4,5-diamino-5-oxopentanoate
WO2019168654A2 (en) 2018-02-09 2019-09-06 President And Fellows Of Harvard College Dna-templated macrocycle library
FR3132644A1 (en) 2022-02-11 2023-08-18 L'oreal Method for screening active ingredients making it possible to prevent the reduction and/or to reinforce the defenses of the skin comprising measuring the level of expression or activity of the IDE

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1038864A1 (en) * 1997-12-12 2000-09-27 Fuji Yakuhin Kogyo Kabushiki Kaisha Novel metalloproteinase inhibitors
EP1101492A1 (en) * 1998-07-17 2001-05-23 Fuji Yakuhin Kogyo Kabushiki Kaisha Novel remedies for allergic diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1038864A1 (en) * 1997-12-12 2000-09-27 Fuji Yakuhin Kogyo Kabushiki Kaisha Novel metalloproteinase inhibitors
EP1101492A1 (en) * 1998-07-17 2001-05-23 Fuji Yakuhin Kogyo Kabushiki Kaisha Novel remedies for allergic diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MORENO, M . ET AL.: "Stereochemically pure a-trifluoromethyl-malic hydroxamates: synthesis and evaluation as inhibitors of matrix metalloproteinases", TETRAHEDRON, vol. 62, no. 43, 2006, pages 10171 - 10181, XP005649828, ISSN: 0040-4020 *
SANI, M. ET AL.: "Synthesis and evaluation of stereopure a-trifluoromethyl-malic hydroxamates as inhibitors of matrix metalloproteinases", TETRAHEDRON LETTERS, vol. 45, no. 8, 2004, pages 1611 - 1615, XP004487111, ISSN: 0040-4039 *

Also Published As

Publication number Publication date
WO2008156701A2 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
WO2008156701A3 (en) Hydroxamate inhibitors of insulin-degrading enzyme and uses thereof
WO2009001097A3 (en) Substrate reduction therapy
WO2007104053A3 (en) 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
WO2009064388A3 (en) Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders
WO2009027346A3 (en) 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-dependent diseases
EP4516352A3 (en) Treatment for diabetes in patients inappropriate for metformin therapy
WO2009072604A1 (en) Anti-nr10 antibody and use thereof
WO2008033562A3 (en) Kinase inhibitor compounds
WO2007100535A3 (en) Oxyntomodulin derivatives
TW200745037A (en) Organic compounds
WO2008022024A3 (en) Imidazole amines as inhibitors of beta-secretase
MX2010007818A (en) Combination therapy comprising sglt inhibitors and dpp4 inhibitors.
UA94455C2 (en) Oxadiazolidinedione compound
ATE554091T1 (en) AMINOTETRAHYDROPYRANS AS DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
WO2008136428A1 (en) Nitrogen-containing five-membered heterocyclic compound
WO2007143600A3 (en) Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
MX2010006823A (en) Methods for the treatment of gout.
NO20064792L (en) Use of rotigotine for the treatment and connection of Parkinson's plus syndrome.
WO2009067856A8 (en) Histone deacetylase inhibitor, composition and use thereof
WO2007083146A3 (en) The treatment of cognitive and psychotic disorders
WO2007121125A3 (en) Hcv inhibitors
WO2008090287A3 (en) Use of at least one botulism neurotoxin for treating the pain induced by therapeutic treatments for the aids virus
MY144970A (en) Heterocyclic compounds
WO2009132149A3 (en) Treatment of conditions related to cecal ligation shock
NZ595364A (en) TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC beta-CELL DYSFUNCTION

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08768474

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08768474

Country of ref document: EP

Kind code of ref document: A2